Modopar 125 Dispersible (Benserazide Hydrochloride, Levodopa)

Levodopa, the active ingredient in Modopar 125 Dispersible, is a dopamine precursor presented as a Levodopa 100 mg / Benserazide Hydrochloride 25 mg dispersible tablet for oral use. It treats Parkinson's disease by restoring central dopamine levels in patients with motor symptoms.

GNH USA supplies Modopar 125 Dispersible as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established quality‑assurance processes and regulatory compliance across EU and other markets. Our distribution network ensures timely delivery and supports local import requirements.

Modopar 125 Dispersible combines levodopa and benserazide to address the dopaminergic deficit in Parkinson's disease. It is used for: - Parkinson's disease (early stage): improves motor function and reduces rigidity. - Parkinson's disease with motor fluctuations: smooths out on‑off periods. - Parkinson's disease with dyskinesia: helps balance dopamine levels and lessen involuntary movements.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Dizziness: sensation of light‑headedness, especially when standing. - Headache: transient cranial discomfort. - Orthostatic hypotension: drop in blood pressure upon standing. - Insomnia: difficulty initiating or maintaining sleep. - Constipation: reduced bowel motility.

Serious or Rare Side Effects: - Hallucinations: visual or auditory disturbances. - Severe hypotension: marked drop in blood pressure requiring medical attention. - Dyskinesia: involuntary, erratic movements. - Cardiac arrhythmias: irregular heart rhythms. - Neuroleptic malignant syndrome: rare, life‑threatening reaction. - Severe allergic reactions: rash, swelling, or breathing difficulty.

Before initiating therapy, consider the following precautions: - Dose titration: start low and increase gradually as directed by the prescriber. - Monitor blood pressure: watch for orthostatic hypotension, especially in the elderly. - Assess renal/hepatic function: adjust dosing if significant impairment is present. - Avoid abrupt discontinuation: sudden stop may worsen Parkinsonian symptoms. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk to the fetus or infant. - Store at below 25°C: keep in the original pack, protect from moisture.

Modopar 125 Dispersible may interact with several medicines.

Major Interactions (Avoid): - MAO‑B inhibitors: risk of hypertensive crisis. - Non‑selective MAO inhibitors: can cause severe hypertension. - Antipsychotics (e.g., haloperidol): may reduce levodopa efficacy. - Anticholinergics: may increase central side effects.

Moderate Interactions (Monitor Closely): - Iron supplements: decrease levodopa absorption; separate dosing by at least 2 hours. - High‑protein meals: may reduce levodopa uptake from the gut. - SSRIs/SNRIs: potential for serotonin syndrome when combined with MAO inhibitors.